These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 31887199)

  • 1. The association between exposure to interferon-beta during pregnancy and birth measurements in offspring of women with multiple sclerosis.
    Burkill S; Vattulainen P; Geissbuehler Y; Sabido Espin M; Popescu C; Suzart-Woischnik K; Hillert J; Artama M; Verkkoniemi-Ahola A; Myhr KM; Cnattingius S; Korhonen P; Montgomery S; Bahmanyar S
    PLoS One; 2019; 14(12):e0227120. PubMed ID: 31887199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon-beta exposure during first trimester is safe in women with multiple sclerosis-A prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry.
    Thiel S; Langer-Gould A; Rockhoff M; Haghikia A; Queisser-Wahrendorf A; Gold R; Hellwig K
    Mult Scler; 2016 May; 22(6):801-9. PubMed ID: 26920382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of adverse pregnancy outcomes after exposure to interferon beta prior to or during pregnancy in women with MS: Stratification by maternal and newborn characteristics in a register-based cohort study in Finland and Sweden.
    Korjagina M; Hakkarainen KM; Burkill S; Geissbühler Y; Sabidó M; Everage N; Suzart-Woischnik K; Klement R; Hillert J; Verkkoniemi-Ahola A; Bahmanyar S; Montgomery S; Korhonen P;
    Mult Scler Relat Disord; 2021 Feb; 48():102694. PubMed ID: 33429303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry.
    Hellwig K; Geissbuehler Y; Sabidó M; Popescu C; Adamo A; Klinger J; Ornoy A; Huppke P;
    J Neurol; 2020 Jun; 267(6):1715-1723. PubMed ID: 32100126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review.
    Lu E; Wang BW; Guimond C; Synnes A; Sadovnick D; Tremlett H
    Neurology; 2012 Sep; 79(11):1130-5. PubMed ID: 22933738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glatiramer acetate during early pregnancy: A prospective cohort study.
    Herbstritt S; Langer-Gould A; Rockhoff M; Haghikia A; Queisser-Wahrendorf A; Gold R; Hellwig K
    Mult Scler; 2016 May; 22(6):810-6. PubMed ID: 26754804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Body dimensions of infants exposed to antiepileptic drugs in utero: observations spanning 25 years.
    Wide K; Winbladh B; Tomson T; Källén B
    Epilepsia; 2000 Jul; 41(7):854-61. PubMed ID: 10897157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perinatal outcomes in women with multiple sclerosis exposed to disease-modifying drugs.
    Lu E; Dahlgren L; Sadovnick A; Sayao A; Synnes A; Tremlett H
    Mult Scler; 2012 Apr; 18(4):460-7. PubMed ID: 21914689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effects of exposure to disease-modifying drugs in the offspring of mothers with multiple sclerosis: a retrospective chart review.
    Fragoso YD; Adoni T; Alves-Leon SV; Azambuja ND; Barreira AA; Brooks JB; Carneiro DS; Carvalho MJ; Claudino R; Comini-Frota ER; Domingues RB; Finkelzstejn A; Gama PD; Giacomo MC; Gomes S; Goncalves MV; Grzesiuk AK; Kaimen-Maciel DR; Mendes MF; Morales NM; Morales RR; Muniz A; Papais-Alvarenga RM; Parolin MK; Ribeiro SB; Ruocco HH; Siquineli F; Tosta ED
    CNS Drugs; 2013 Nov; 27(11):955-61. PubMed ID: 24114585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between patterns of maternal substance use and infant birth weight, length, and head circumference.
    Shankaran S; Das A; Bauer CR; Bada HS; Lester B; Wright LL; Smeriglio V
    Pediatrics; 2004 Aug; 114(2):e226-34. PubMed ID: 15286261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of potential breast milk exposure to IFN-β or glatiramer acetate: One-year infant outcomes.
    Ciplea AI; Langer-Gould A; Stahl A; Thiel S; Queisser-Wahrendorf A; Gold R; Hellwig K
    Neurol Neuroimmunol Neuroinflamm; 2020 Jul; 7(4):. PubMed ID: 32434802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use and safety of disease-modifying therapy in pregnant women with multiple sclerosis.
    MacDonald SC; McElrath TF; Hernández-Díaz S
    Pharmacoepidemiol Drug Saf; 2019 Apr; 28(4):556-560. PubMed ID: 30834654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relation of in-utero exposure to antiepileptic drugs to pregnancy duration and size at birth.
    Margulis AV; Hernandez-Diaz S; McElrath T; Rothman KJ; Plana E; Almqvist C; D'Onofrio BM; Oberg AS
    PLoS One; 2019; 14(8):e0214180. PubMed ID: 31381574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of interferon beta exposure on birth outcome and child development - Results from the post-authorisation safety study PRIMA.
    Klehmet J; Begus-Nahrmann Y; Taipale K; Niemczyk G; Rehberg-Weber K
    Mult Scler Relat Disord; 2023 Sep; 77():104844. PubMed ID: 37393802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neonatal growth outcomes at birth and one month postpartum following in utero exposure to antidepressant medication.
    Lewis AJ; Galbally M; Opie G; Buist A
    Aust N Z J Psychiatry; 2010 May; 44(5):482-7. PubMed ID: 20397792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Birth outcomes in newborns fathered by men with multiple sclerosis exposed to disease-modifying drugs.
    Lu E; Zhu F; Zhao Y; van der Kop M; Synnes A; Dahlgren L; Sadovnick AD; Traboulsee A; Tremlett H
    CNS Drugs; 2014 May; 28(5):475-82. PubMed ID: 24643915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth of infants prenatally exposed to cocaine/crack: comparison of a prenatal care and a no prenatal care sample.
    Richardson GA; Hamel SC; Goldschmidt L; Day NL
    Pediatrics; 1999 Aug; 104(2):e18. PubMed ID: 10429136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis.
    Sandberg-Wollheim M; Frank D; Goodwin TM; Giesser B; Lopez-Bresnahan M; Stam-Moraga M; Chang P; Francis GS
    Neurology; 2005 Sep; 65(6):802-6. PubMed ID: 16093457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pregnancy outcomes after exposure to interferon beta: a register-based cohort study among women with MS in Finland and Sweden.
    Hakkarainen KM; Juuti R; Burkill S; Geissbühler Y; Sabidó M; Popescu C; Suzart-Woischnik K; Hillert J; Artama M; Verkkoniemi-Ahola A; Myhr KM; Mehtälä J; Bahmanyar S; Montgomery S; Korhonen P
    Ther Adv Neurol Disord; 2020; 13():1756286420951072. PubMed ID: 33101459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parenthood and immunomodulation in patients with multiple sclerosis.
    Hellwig K; Haghikia A; Gold R
    J Neurol; 2010 Apr; 257(4):580-3. PubMed ID: 19936821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.